75000 - Document - Document and Entity Information
link:presentationLink
link:calculationLink
link:definitionLink
75010 - Statement - Condensed Consolidated Balance Sheets (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
75020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
75030 - Statement - Condensed Consolidated Statements of Operations (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
75040 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
75050 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
75060 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
995455 - Disclosure - Organization and Description of Business
link:presentationLink
link:calculationLink
link:definitionLink
995465 - Disclosure - Significant Accounting Policies
link:presentationLink
link:calculationLink
link:definitionLink
995475 - Disclosure - Revenue
link:presentationLink
link:calculationLink
link:definitionLink
995485 - Disclosure - Deferred Revenue
link:presentationLink
link:calculationLink
link:definitionLink
995495 - Disclosure - Fair Value Measurements
link:presentationLink
link:calculationLink
link:definitionLink
995505 - Disclosure - Investments
link:presentationLink
link:calculationLink
link:definitionLink
995515 - Disclosure - Leases
link:presentationLink
link:calculationLink
link:definitionLink
995525 - Disclosure - Revenue Interest Purchase Agreement
link:presentationLink
link:calculationLink
link:definitionLink
995535 - Disclosure - Commitments and Contingencies
link:presentationLink
link:calculationLink
link:definitionLink
995545 - Disclosure - Shareholders' Equity
link:presentationLink
link:calculationLink
link:definitionLink
995555 - Disclosure - Equity Incentive Plans
link:presentationLink
link:calculationLink
link:definitionLink
995565 - Disclosure - Restructurings
link:presentationLink
link:calculationLink
link:definitionLink
995575 - Disclosure - Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders
link:presentationLink
link:calculationLink
link:definitionLink
995585 - Disclosure - Segment Information
link:presentationLink
link:calculationLink
link:definitionLink
995595 - Disclosure - Significant Accounting Policies (Policies)
link:presentationLink
link:calculationLink
link:definitionLink
995605 - Disclosure - Significant Accounting Policies (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995615 - Disclosure - Revenue (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995625 - Disclosure - Deferred Revenue (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995635 - Disclosure - Fair Value Measurements (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995645 - Disclosure - Investments (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995655 - Disclosure - Leases (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995665 - Disclosure - Revenue Interest Purchase Agreement (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995675 - Disclosure - Shareholders' Equity (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995685 - Disclosure - Equity Incentive Plans (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995695 - Disclosure - Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995705 - Disclosure - Segment Information (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995715 - Disclosure - Significant Accounting Policies - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995725 - Disclosure - Significant Accounting Policies - Schedule of Concentrations of Risk Percentage (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995735 - Disclosure - Revenue - Schedule of Disaggregated Revenue (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995745 - Disclosure - Revenue - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995755 - Disclosure - Deferred Revenue - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995765 - Disclosure - Deferred Revenue - Additional Information (Details1)
link:presentationLink
link:calculationLink
link:definitionLink
995765 - Disclosure - Deferred Revenue - Additional Information (Details1) [Default]
link:presentationLink
link:calculationLink
link:definitionLink
995775 - Disclosure - Deferred Revenue - Schedule of Changes in Deferred Revenue (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995785 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995795 - Disclosure - Fair Value Measurements - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995805 - Disclosure - Investments - Schedule of Available-for-sale Investments (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995815 - Disclosure - Investments - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995825 - Disclosure - Investments - Schedule of Gross Unrealized Holding Losses and Fair Values for Investments in Unrealized Loss Position (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995835 - Disclosure - Leases - Summary of Reconciles Undiscounted Operating Lease Cash Flows (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995845 - Disclosure - Leases - Summary of Reconciles Undiscounted Operating Lease Cash Flows (Details) 2
link:presentationLink
link:calculationLink
link:definitionLink
995855 - Disclosure - Leases - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995865 - Disclosure - Revenue Interest Purchase Agreement - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995875 - Disclosure - Revenue Interest Purchase Agreement - Schedule of Revenue Interest Liability, Net Activity (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995885 - Disclosure - Shareholders' Equity - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995895 - Disclosure - Shareholders' Equity - Summary of Reserved Shares of Common Stock (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995905 - Disclosure - Equity Incentive Plans - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995915 - Disclosure - Equity Incentive Plans - Summary of Changes in Shares Available for Grant (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995925 - Disclosure - Equity Incentive Plans - Summary of Stock Option Activity Under 2009 Plan and 2019 Plan (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995935 - Disclosure - Equity Incentive Plans - Summary of Restricted Stock Unit and Market-Based Restricted Stock Units Activity (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995945 - Disclosure - Equity Incentive Plans - Summary of Estimated Grant Date Fair Value of Stock Options Granted (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995955 - Disclosure - Equity Incentive Plans - Summary of Compensation Costs Related to Stock Options and RSUs Included on Unaudited Condensed Consolidated Statements of Operations (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995965 - Disclosure - Equity Incentive Plans - Schedule of Unrecognized Share-Based Compensation Expense and the Remaining Weighted-Average Recognition Period (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995975 - Disclosure - Restructurings - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995985 - Disclosure - Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995995 - Disclosure - Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996005 - Disclosure - Segment Information - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996015 - Disclosure - Segment Information - Schedule of Segment Information, Including Significant Segment Expenses (Details)
link:presentationLink
link:calculationLink
link:definitionLink
Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Vested
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
Weighted Average Exercise Price per Share, Stock Options forfeited
Segments [Domain]
Software Enhancements
Software Development [Member]
Concentration Risk Type
Concentration Risk Type [Axis]
Inventory reserve.
Inventory Reserve
Inventory reserve
Entity Incorporation, State or Country Code
Entity Incorporation, State or Country Code
Preferred stock issued
Preferred Stock, Shares Issued
Balance Sheet Location
Statement of Financial Position Location, Balance [Domain]
Noncash investing and financing activities
Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]
Noncash investing activities
Long-Term Debt, Excluding Current Maturities
Long-Term Debt, Excluding Current Maturities, Total
Revenue interest liability, net, less current portion
Plan Name
Plan Name [Axis]
12 months or greater, Fair value
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer
Equity [Abstract]
Entity Current Reporting Status
Entity Current Reporting Status
Operating expenses
Operating Expenses [Abstract]
Level 2
Fair Value, Inputs, Level 2 [Member]
Commitments and Contingencies
Commitments and Contingencies Disclosure [Text Block]
Common stock authorized
Common Stock, Shares Authorized
Customer A
Customer A [Member]
Customer A.
Product and Service [Axis]
Product and Service
Document Fiscal Period Focus
Document Fiscal Period Focus
Effective interest rate
Debt Instrument, Interest Rate, Stated Percentage
Revenue from Contract with Customer [Abstract]
Entity Shell Company
Entity Shell Company
2019 Equity Incentive Plan
Two Thousand And Nineteen Equity Incentive Plan [Member]
Two thousand and nineteen equity incentive plan.
Service Revenue
Service [Member]
Service and Licensing Revenue
Segment Reporting, Policy [Policy Text Block]
Segment Information
Cash and Cash Equivalents, at Carrying Value, Total
Cash and cash equivalents
Cash and Cash Equivalent
Cash and cash equivalents at end of period
Impairment of Long Lived Assets
Impairment of long lived assets.
Impairment of long-lived assets
Shares Subject to Outstanding Stock Options, Stock Options vested and exercisable
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable
Share based compensation arrangement by share based payment award options vested and exercisable.
Common stock issued
Common Stock, Shares, Issued
Asset Class
Asset Class [Domain]
Statement [Table]
Statement [Table]
Stock Options And Restricted Stock Units Granted And The Maximum Performance-based And Market-based Restricted Stock Units Granted Eligible To Be Earned
Stock options and restricted stock units granted and the maximum performance-based and market-based restricted stock units granted eligible to be earned.
Stock options and restricted stock units granted and the maximum performance-based and market-based restricted stock units granted eligible to be earned
Restricted cash
Restricted Cash, Noncurrent
Restricted cash at end of period
Fair value of common stock
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Items To Reconcile Net Loss To Adjusted EBITDA
Items to reconcile net loss to adjusted EBITDA.
Items to reconcile net loss to adjusted EBITDA
Statement [Line Items]
Statement [Line Items]
Revenue Recognition
Revenue from Contract with Customer [Policy Text Block]
Weighted Average Exercise Price per Share, Stock Options expired
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
Entity Filer Category
Entity Filer Category
Restricted Stock Units Outstanding
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Total liabilities and shareholders’ equity
Liabilities and Equity
Long-Term Debt, Current Maturities
Long-Term Debt, Current Maturities, Total
Current portion of revenue interest liability, net
Purchases of marketable securities
Payments to Acquire Marketable Securities
Restructuring Type [Axis]
Potential revenue interest third payment to be received
Potential Revenue Interest Third Payment To Be Received
Potential revenue interest third payment to be received.
Long-Lived Tangible Asset [Axis]
Prepaid Expenses and Other Current Assets
Prepaid Expenses and Other Current Assets [Member]
Percentage of annual increases in number of shares
Percentage Of Annual Increases In Number Of Shares
Percentage of annual increases in number of shares.
Performance based restricted stock units [Member]
Performance based restricted stock units.
Performance-Based Restricted Stock Units
Cash and Cash Equivalents, Fair Value Disclosure
Cash and cash equivalents
Goodwill, Ending Balance
Goodwill, Beginning Balance
Goodwill, Total
Goodwill
Goodwill
Other Noncash Income (Expense), Total
Other
Other Noncash Income (Expense)
Employee Stock Option
Debt Securities, Available-for-Sale, Noncurrent
Long-term marketable securities (amortized cost of $18,908 and $13,220, respectively)
Restricted Cash
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]
Nonvested Restricted Stock Units
Nonvested Restricted Stock Units R S U [Member]
Nonvested Restricted Stock Units R S U.
Long-term assets
Assets, Noncurrent [Abstract]
Schedule of Unrecognized Share-Based Compensation Expense and the Remaining Weighted-Average Recognition Period
Schedule Of Unrecognized Share Based Compensation Expense And The Expected Weighted Average Remaining Recognition Period Table [Text Block]
Schedule of unrecognized share-based compensation expense and the expected weighted-average remaining recognition period.
Sequencing revenue.
Sequencing Revenue [Member]
Sequencing Revenue
Capitalized issuance costs
Debt issuance costs
Debt Issuance Costs, Net
Debt Issuance Costs, Net, Total
Significant Accounting Policies
Significant Accounting Policies [Text Block]
Shares Subject to Outstanding Stock Options, Stock Options granted
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross
Disaggregation Of Revenue [Table]
Disaggregation of Revenue [Table]
Computation of the Basic and Diluted Net Loss Per Share Attributable to Common Shareholders
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
Increase (Decrease) in Other Operating Assets and Liabilities, Net, Total
Other
Increase (Decrease) in Other Operating Assets and Liabilities, Net
Earnings Per Share, Basic
Earnings Per Share, Basic, Total
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic
Schedule of Disaggregated Revenue
Disaggregation of Revenue [Table Text Block]
Shares Subject to Outstanding Stock Options, Stock Options outstanding, Beginning Balance
Shares Subject to Outstanding Stock Options, Stock Options outstanding, Ending Balance
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Weighted-average grant date fair value per share
Schedule of Available-for-sale Investments
Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]
Customer C
Customer C [Member]
Customer C member
Digital Biotechnologies Inc
Digital Biotechnologies Inc [Member]
Digital Biotechnologies, Inc.
Sharon Benzeno.
Sharon Benzeno [Member]
Total current liabilities
Liabilities, Current
Accounts receivable, net
Increase (Decrease) in Accounts Receivable
Adjustments to reconcile net loss to net cash used in operating activities
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]
Revenue interest payable
Revenue Interest Payable
Revenue Interest Payable
Revenue interest payable
Chad Robins [Member]
Chad Robins
Consolidation Items [Domain]
Shareholders’ equity
Equity, Attributable to Parent [Abstract]
Entity Small Business
Entity Small Business
Retained Earnings (Accumulated Deficit), Total
Accumulated deficit
Retained Earnings (Accumulated Deficit)
Deferred Revenue
Deferred Revenue [Text Block]
Deferred revenue.
Mrd Business Segment And Immune Medicine Business Segment [Member]
Mrd business segment and immune medicine business segment.
MRD and Immune Medicine
Equity Incentive Plans
Share-Based Payment Arrangement [Text Block]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Revenue Interest Purchase Agreement
Revenue Interest Purchase Agreement [Text Block]
Revenue interest purchase agreement.
Contract with Customer, Liability, Total
Contract with Customer, Liability
Deferred revenue
Deferred revenue balance at March 31, 2026
Deferred revenue balance at December 31, 2025
Amendment Flag
Amendment Flag
Product and Service
Product and Service [Domain]
Liabilities and shareholders’ equity
Liabilities and Equity [Abstract]
Entity Address, Postal Zip Code
Entity Address, Postal Zip Code
Net cash used in operating activities
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Common Stock
Common Stock [Member]
Weighted Average Exercise Price per Share, Stock Options granted
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Accrued interest receivable
Interest Receivable, Current
Lessee, Operating Lease, Liability, to be Paid, Year Three
2029
Schedule of Available-for-Sale Securities [Line Items]
Debt Securities, Available-for-Sale [Line Items]
Entity Address, Address Line One
Entity Address, Address Line One
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
Summary of Estimated Grant Date Fair Values of Stock Options Granted
Fair Value Hierarchy and NAV
Fair Value Hierarchy and NAV [Axis]
Earnings Per Share [Abstract]
Supplemental Cash Flow Information [Abstract]
Supplemental disclosure of cash flow information
Balance Sheet Location
Statement of Financial Position Location, Balance [Axis]
Investment Type
Investment Type [Axis]
2009 Equity Incentive Plan
Two Thousand And Nine Equity Incentive Plan [Member]
Two thousand and nine equity incentive plan.
Operating lease right-of-use assets
Operating Lease, Right-of-Use Asset
MRD Revenue
M R D Revenue [Member]
MRD Revenue.
Schedule of Revenue Interest Liability, Net Activity
Schedule of Revenue Interest Liability, Net Activity [Table Text Block]
Schedule of revenue interest liability, net activity.
Net Income (Loss) Attributable to Noncontrolling Interest, Total
Net Income (Loss) Attributable to Noncontrolling Interest
Net loss attributable to noncontrolling interest
Net loss attributable to noncontrolling interest
Add: Net income attributable to noncontrolling interest
Document Type
Document Type
Collaborative Arrangement and Arrangement Other than Collaborative
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Shares Issuable Upon the Vesting of Outstanding Restricted Stock Units and the Maximum Outstanding Market-based Restricted Stock Units Granted
Common Stock Vesting Of Outstanding Restricted Stock Units And Market Based Restricted Stock Units Granted [Member]
Common stock vesting of outstanding restricted stock units and market-based restricted stock units granted.
Ownership interest percentage
Subsidiary, Ownership Percentage, Parent
Collaborative Arrangement and Arrangement Other than Collaborative
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Entity Central Index Key
Entity Central Index Key
Investments, Debt and Equity Securities [Abstract]
Common Stock Vesting of Outstanding Restricted Stock Units and Performance-based Restricted Stock Units and Maximum Market Based Restricted Stock Units Granted [Member]
Common stock vesting of outstanding restricted stock units and performance-based restricted stock units and maximum market based restricted stock units granted.
Shares Issuable Upon the Vesting of Outstanding Restricted Stock Units Granted and the Maximum Outstanding Performance-based and Market-based Restricted Stock Units Granted
Valuation Approach and Technique
Valuation Approach and Technique [Axis]
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Net increase in cash, cash equivalents and restricted cash
Antidilutive securities
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Genentech collaboration agreement.
Genentech Collaboration Agreement
Genentech Collaboration Agreement [Member]
Common stock par value
Common Stock, Par or Stated Value Per Share
Shares Issuable Upon the Exercise of Outstanding Stock Options Granted
Common Stock Exercise Of Outstanding Stock Options Granted [Member]
Common stock exercise of outstanding stock options granted.
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Total
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Other comprehensive loss
Other comprehensive loss
Amortization of purchase agreement obligation
Amortization of Purchase Agreement obligation
Amortization of purchase agreement obligation.
Weighted-average remaining contractual life stock options outstanding
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term
Expected volatility, maximum
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum
Amortized Cost
Debt Securities, Available-for-Sale, Amortized Cost
Share Based Compensation Arrangement By Share Based Payment Awards Stock options, restricted stock units and Performance-based restricted stock units forfeited or expired
Share Based Compensation Arrangement By Share Based Payment Awards Stock options, restricted stock units and Performance-based restricted stock units forfeited or expired
Stock options, restricted stock units and performance-based restricted stock units forfeited or expired
Stock options, restricted stock units and performance-based restricted stock units forfeited or expired
Short-term marketable securities (amortized cost of $295,689 and $214,115, respectively)
Debt Securities, Available-for-Sale, Total
Estimated Fair Value
Debt Securities, Available-for-Sale
Shares Subject to Outstanding Stock Options, Stock Options exercised
Issuance of common stock for cash upon exercise of stock options, Shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period
Long-Term Marketable Securities
Available For Sale Securities Debt Securities Noncurrent [Member]
Available for sale securities debt securities noncurrent.
Accrued Liabilities, Current, Total
Accrued liabilities
Accrued Liabilities, Current
Cost of Revenue
Cost of Sales [Member]
Ownership
Ownership [Domain]
Current Fiscal Year End Date
Current Fiscal Year End Date
Regulatory milestones.
Regulatory Milestones
Regulatory Milestones [Member]
Document Quarterly Report
Document Quarterly Report
Entity Address, State or Province
Entity Address, State or Province
Restricted Stock Units Outstanding, Nonvested Outstanding, Ending Balance
Restricted Stock Units Outstanding, Nonvested Outstanding, Beginning Balance
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Restricted stock units outstanding
Preferred Stock, Shares Outstanding, Ending Balance
Preferred Stock, Shares Outstanding, Beginning Balance
Preferred stock outstanding
Preferred Stock, Shares Outstanding
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive loss attributable to Adaptive Biotechnologies Corporation
Unrealized Gain
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax
Total shares of common stock reserved for future issuance
Common Stock, Capital Shares Reserved for Future Issuance
Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements
Incremental shares attributable to share-based compensation plans
Revenue recognized
Revenue recognized during the period
Contract with Customer, Liability, Revenue Recognized
Accounts Receivable, Net
Accounts Receivable [Member]
Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance
Stockholders' Equity Attributable to Noncontrolling Interest, Beginning Balance
Stockholders' Equity Attributable to Noncontrolling Interest, Total
Noncontrolling interest
Equity, Attributable to Noncontrolling Interest
Noncontrolling interest
Potential revenue interest second payment to be received
Potential Revenue Interest Second Payment To Be Received
Potential revenue interest second payment to be received.
Summary of Compensation Costs Related to Stock Options and RSUs Included on Unaudited Condensed Consolidated Statements of Operations
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
Issuance of common stock for cash upon exercise of stock options
Stock Issued During Period, Value, Stock Options Exercised
Interest and other income, net
Interest and Other Income
Interest and other income, net
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Other comprehensive loss
Proceeds from maturities of marketable securities
Proceeds from Sale and Maturity of Marketable Securities
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized
Increase in share reserve
Summary of Reserved Shares of Common Stock
Schedule Of Reserved Shares Of Common Stock Table [Text Block]
Schedule of reserved shares of common stock.
Other assets
Other Assets, Noncurrent
Debt Securities, Available-for-Sale, Current
Short-term marketable securities (amortized cost of $140,762 and $156,246, respectively)
Number of vote for each share
Number Of Common Stock Voting Rights
Number of common stock voting rights.
Shares Subject to Outstanding Stock Options, Stock Options expired
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period
Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent
Amortized cost of long-term marketable securities
Other unallocated items
Segment Reporting Other Unallocated Items
Segment reporting other unallocated items.
Expected revenue through milestone payments
Revenue Recognition Milestone Method Expected Milestone Receivable
Revenue recognition milestone method expected milestone receivable.
Interest expense
Interest Expense, Debt
Interest Expense, Debt, Total
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Gain (Loss)
Customer
Customer [Domain]
Preferred Stock, Value, Issued
Preferred stock: $0.0001 par value, 10,000,000 shares authorized at March 31, 2026 and December 31, 2025; no shares issued and outstanding at March 31, 2026 and December 31, 2025
Minimum
Minimum [Member]
Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Granted
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value
Grant date fair value
Financial Instrument [Axis]
Current assets
Assets, Current [Abstract]
Contract With Customer Liability Revenue Recognized During The Period
Contract With Customer Liability Revenue Recognized During The Period
Revenue recognized during the period
Intangible assets amortization
Amortization of intangible assets
Amortization of Intangible Assets
Level 3
Fair Value, Inputs, Level 3 [Member]
Share Based Compensation Arrangement By Share Based Payement Equity Incentive Plan Reserve
Share Based Compensation Arrangement By Share Based Payement Equity Incentive Plan Reserve
2019 Equity Incentive Plan reserve increase effective January 1, 2026
Segment Reporting [Abstract]
Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]
Current liabilities
Liabilities, Current [Abstract]
Nonvested Stock Options
Nonvested Stock Options [Member]
Nonvested Stock Options.
Restructurings
Restructuring and Related Activities Disclosure [Text Block]
Beginning Balance, Shares
Ending Balance, Shares
Shares, Outstanding
Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]
Schedule of Gross Unrealized Holding Losses and Fair Values for Investments in Unrealized Loss Position
Accounts Receivable, after Allowance for Credit Loss, Current, Total
Accounts receivable, net
Accounts Receivable, after Allowance for Credit Loss, Current
Revenue interest payment term
Revenue Interest Payment Term
Revenue interest payment term.
Commitments and Contingencies
Commitments and contingencies (Note 9)
Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Beginning Balance
Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Ending Balance
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Weighted-average grant date fair value per share
General and Administrative
General and Administrative Expense [Member]
Total operating lease liabilities
Operating Lease, Liability
Revenue
Concentration Risk Benchmark [Axis]
Summary of Changes in Shares Available for Grant
Schedule Of Share Based Compensation Shares Available For Grant Table [Text Block]
Schedule of share-based compensation, shares available for grant.
Long-term liabilities
Liabilities, Noncurrent [Abstract]
Purchases of equipment included in accounts payable and accrued liabilities
Capital Expenditures Incurred but Not yet Paid
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Net (loss) income
Net loss
Net loss
Monte Carlo Valuation Model
Monte Carlo Valuation Model [Member]
Monte Carlo Valuation Model.
Weighted Average Number of Shares Outstanding, Basic, Total
Weighted Average Number of Shares Outstanding, Basic
Weighted-average shares outstanding - basic
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic
Revenue interest liability, net
Revenue interest liability, net
Revenue Interest Liability, Net
Revenue interest liability, net
Revenue interest liability, net
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
12 months or greater, Unrealized loss
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss
Segments [Axis]
Long-Lived Tangible Asset [Domain]
Number of reportable segments disclosed by definition flag
Number Of Reportable Segments Disclosed By Definition Flag
Number of reportable segments disclosed by definition flag.
Items To Reconcile Net Income or Net Loss To Adjusted EBITDA
Items to reconcile net income or net loss to adjusted EBITDA.
Items to reconcile net income or net loss to Adjusted EBITDA(3)
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
Share-based compensation expense
Share-based compensation expense
M R D service revenue.
M R D Service Revenue [Member]
MRD Service Revenue
Thereafter
Lessee Operating Lease Liability Payments Due After Year Four
Lessee operating lease liability payments due after year four.
Stockholders' Equity Attributable to Parent, Ending Balance
Stockholders' Equity Attributable to Parent, Beginning Balance
Total Adaptive Biotechnologies Corporation shareholders’ equity
Equity, Attributable to Parent
Preferred stock par value
Preferred Stock, Par or Stated Value Per Share
Unaudited Interim Condensed Consolidated Financial Statements
Unaudited Interim Financial Statements Policy [Text Block]
Unaudited interim financial statements policy text block.
Statement of Stockholders' Equity [Abstract]
Type of Restructuring [Domain]
Valuation Approach and Technique
Valuation Approach and Technique [Domain]
Use of Estimates
Use of Estimates, Policy [Policy Text Block]
Leasehold Improvements
Leasehold Improvements [Member]
Sales and Marketing
Selling and Marketing Expense [Member]
Fair Value Measurements
Fair Value Disclosures [Text Block]
Noncontrolling Interest
Noncontrolling Interest [Member]
Segment Reporting, Other Segment Item, Amount
Other segment items
Plan Name
Plan Name [Domain]
Interest expense
Interest expense
Interest Expense, Operating and Nonoperating
Interest Expense, Total
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]
OrbiMed
OrbiMed Royalty & Credit Opportunities IV, LP [Member]
OrbiMed Royalty & Credit Opportunities IV, LP.
Cost of Goods and Services Sold, Total
Cost of revenue
Cost of Product and Service Sold
Impairment of long-lived assets
Impairment, Long-Lived Asset, Held-for-Use
Impairment, Long-Lived Asset, Held-for-Use, Total
Impairment of long-lived assets
Organization and Description of Business
Business Description and Basis of Presentation [Text Block]
Aggregate Intrinsic Value, Stock Options vested and exercisable
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Intrinsic Value
Share based compensation arrangement by share based payment award options vested and exercisable intrinsic value.
Potential revenue interest payment to be received
Potential Revenue Interest Payment To Be Received
Potential revenue interest payment to be received.
Cancelled Customer Contracts
Cancelled Customer Contracts [Member]
Cancelled customer contracts.
Entity Address, City or Town
Entity Address, City or Town
Security Exchange Name
Security Exchange Name
Commercial Milestones
Commercial Milestones [Member]
Commercial milestones.
Stock Issued During Period Shares Restricted Stock Award And Market-based Restricted Stock Units Vested
Stock issued during period shares restricted stock award and market-based restricted stock units vested.
Vesting of restricted stock units and market-based restricted stock units
Intersegment Eliminations [Member]
Unallocated Corporate
Inter-segment
Counterparty Name [Axis]
Concentration Risk Type
Concentration Risk Type [Domain]
Significant Accounting Policies [Line Items]
Significant Accounting Policies [Line Items]
Significant accounting policies.
Contract with Customer, Duration [Domain]
Purchase Agreement
Purchase Agreement [Member]
Purchase agreement.
Inventory, Net, Total
Inventory, Net
Inventory
Interest Paid, Excluding Capitalized Interest, Operating Activity
Cash paid for interest
Statistical Measurement
Statistical Measurement [Domain]
Total current assets
Assets, Current
Total share-based compensation expense
Recognized share-based compensation expense
Share-based compensation expense
Share-based compensation expense
Document Period End Date
Document Period End Date
Title of Individual
Title and Position [Axis]
Fair Value Hierarchy and NAV
Fair Value Hierarchy and NAV [Domain]
Nonvested Market-Based Restricted Stock Units
Nonvested Market Based Restricted Stock Units [Member]
Nonvested market-based restricted stock units.
Statement of Financial Position [Abstract]
Restricted Stock Units (RSUs)
Restricted Stock Units (RSUs) [Member]
Reconciliation of cash, cash equivalents and restricted cash at end of period
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract]
Noncash interest expense.
Noncash Interest Expense
Noncash interest expense
Non Employee Directors
Non Employee Directors [Member]
Non-employee directors.
Francis Lo [Member]
Francis Lo.
Total liabilities
Liabilities
US Government Debt Securities [Member]
U.S. Government Treasury and Agency Securities
Financial Instruments [Domain]
Number of operating and reportable segments.
Number of Operating and Reportable Segments
Number of operating and reportable segments
Option Valuation Model
Valuation Technique, Option Pricing Model [Member]
Lessee, Operating Lease, Liability, to be Paid, Year Two
2028
Commercial and Sales Based Milestone Payments Eligible to Receive
Commercial and Sales Based Milestone Payments Eligible to Receive.
Commercial and Sales Based Milestone Payments Eligible to Receive
Customer B
Customer B [Member]
Customer B.
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss
Less than 12 months, Unrealized Loss
Weighted Average Number of Shares Outstanding, Diluted, Total
Weighted Average Number of Shares Outstanding, Diluted
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted
Entity File Number
Securities Act File Number
Change in unrealized gains and losses on investments
OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax
Cover [Abstract]
Expected volatility, minimum
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum
Revenue interest purchase agreement interest
Revenue Interest Purchase Agreement Interest
Revenue interest purchase agreement interest.
Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total
Accounts payable and accrued liabilities
Increase (Decrease) in Accounts Payable and Accrued Liabilities
Prepaid expenses and other current assets
Prepaid Expense and Other Assets, Current
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Restricted Stock Units Outstanding, Forfeited
Adjusted EBITDA.
Adjusted EBITDA
Adjusted EBITDA
Adjusted EBITDA
Investments
Investments [Domain]
Revenue
Revenue Benchmark [Member]
Number of shares authorized for issuance
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized
Number of operating segments
Number of Operating Segments
Sale of Stock
Sale of Stock [Domain]
Segment Reporting Disclosure [Text Block]
Segment Information
General and Administrative Expense, Total
General and administrative
General and Administrative Expense
Harlan Robins [Member]
Harlan Robins
Regulatory Milestone Revenue
Regulatory Milestone Revenue [Member]
Regulatory Milestone Revenue.
Contract with Customer, Duration [Axis]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Total
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period
Shares Subject to Outstanding Stock Options, Stock Options forfeited
Development Milestones
Development Milestones [Member]
Development milestones.
Nonvested Performance-based Restricted Stock Units
Nonvested Performance-based Restricted Stock Units [Member]
Nonvested Performance-based Restricted Stock Units [Member]
Finite-Lived Intangible Assets, Net
Finite-Lived Intangible Assets, Net, Ending Balance
Finite-Lived Intangible Assets, Net, Beginning Balance
Net Carrying Amount
Intangible assets, net
Restructuring expense
Restructuring Charges
Restructuring Charges, Total
New Accounting Pronouncements, Policy [Policy Text Block]
New Accounting Pronouncements Not Yet Adopted
Summary of Reconciles Undiscounted Operating Lease Cash Flows
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]
Current deferred revenue
Current portion of deferred revenue
Contract with Customer, Liability, Current
Ownership [Axis]
Ownership
Vesting period
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period
Ongoing Benefit Arrangements
Employee Severance [Member]
Immune Medicine Revenue
Immune Medicine Revenue [Member]
Immune Medicine Revenue.
Operating lease right-of-use assets and liabilities
Increase Decrease In Operating Lease Right Of Use Assets And Liabilities
Increase (decrease) in operating lease right-of-use assets and liabilities .
Risk-free interest rate, minimum
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
Depreciation, Total
Depreciation expense
Depreciation
Number of revenue performance obligation.
Number Of Revenue Performance Obligation
Number of revenue performance obligations
Short-Term Contract with Customer [Member]
Short-Term Contract with Customer
Common Stock, Shares, Outstanding, Ending Balance
Common Stock, Shares, Outstanding, Beginning Balance
Common stock outstanding
Common Stock, Shares, Outstanding
Less: Current portion
Current portion of operating lease liabilities
Operating Lease, Liability, Current
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Document Transition Report
Document Transition Report
Research and Development Expense, Total
Research and development
Research and Development Expense
Asset Impairment Charges
Asset Impairment Charges, Total
Impairment charges
Leases
Lessee, Operating Leases [Text Block]
Genentech, Inc.
Genentech Inc [Member]
Genentech Inc.
Amortized cost of short-term marketable securities
Debt Securities, Available-for-Sale, Amortized Cost, Current
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest
Comprehensive loss
Statement of Cash Flows [Abstract]
Weighted-Average Grant Date Fair Value per Share
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Summary of Stock Option Activity Under 2009 Plan and 2019 Plan
Share-Based Payment Arrangement, Option, Activity [Table Text Block]
Financial assets
Assets, Fair Value Disclosure [Abstract]
Shareholders' Equity
Equity [Text Block]
Earnings Per Share [Text Block]
Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders
Net loss attributable to Adaptive Biotechnologies Corporation
Net loss attributable to Adaptive Biotechnologies Corporation
Aggregate Intrinsic Value, Stock Option outstanding
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Write-off of inventory
Inventory Write-down
Increase (Decrease) in Inventories, Total
Inventory
Increase (Decrease) in Inventories
Short-Term Marketable Securities
Available For Sale Securities Debt Securities Current [Member]
Available for sale securities debt securities current.
Expected dividend yield
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Operating Lease, Payments
Cash paid for amounts included in measurement of lease liabilities
Assets
Assets [Abstract]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Risk-free interest rate
Prepaid expenses and other current assets
Increase (Decrease) in Prepaid Expense and Other Assets
Restructuring and Related Activities [Abstract]
Document Fiscal Year Focus
Document Fiscal Year Focus
Concentration Risk Benchmark
Concentration Risk Benchmark [Domain]
Deferred revenue, expected to be recognized
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period
Investing activities
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]
Accounts Payable, Current, Total
Accounts payable
Accounts Payable, Current
Research and Development
Research and Development Expense [Member]
Investments
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]
Market-Based Restricted Stock Units
Market Based Restricted Stock Units R S U [Member]
Market-Based Restricted Stock Units R S U.
Schedule of Changes in Deferred Revenue
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]
Restructuring Cost and Reserve [Line Items]
Immune Medicine Service Revenue
Immune Medicine Service Revenue [Member]
Immune medicine service revenue.
Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]
Summary of Restricted Stock Unit and Market-Based Restricted Stock Units Activity
Service And Licensing Revenue [Member]
Service and licensing revenue.
Service and Licensing Revenue
Proceeds from exercise of stock options
Proceeds from Stock Options Exercised
Fair Value Disclosures [Abstract]
Commitments and Contingencies Disclosure [Abstract]
Lessee, Operating Lease, Liability, to be Paid, Year One
2027
Significant Accounting Policies [Table]
Significant Accounting Policies [Table]
Significant accounting policies.
Kyle Piskel [Member]
Kyle Piskel.
Share-Based Payment Arrangement [Abstract]
Assets, Fair Value Disclosure, Total
Total financial assets
Assets, Fair Value Disclosure
Sale of Stock
Sale of Stock [Axis]
Concentration risk, percentage
Concentration Risk, Percentage
Revenues, Total
Revenues
Revenue
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
Net cash provided by investing activities
Upfront payment received
Upfront Payment Received
Upfront payment received.
Title of 12(b) Security
Title of 12(b) Security
Schedule of Segment Reporting Information, by Segment [Table]
Grant date fair value forfeited
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
Weighted-Average Grant Date Fair Value per Share, Nonvested Outstanding, Forfeited
Purchase agreement, third payment date
Purchase Agreement Third Payment Date
Purchase agreement third payment date.
Money Market Funds
Money Market Funds [Member]
Collaboration Revenue
Collaboration Revenue [Member]
Collaboration Revenue.
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year
2026 (excluding the three months ended March 31, 2026)
Other long-term liabilities
Other Liabilities, Noncurrent
Changes in operating assets and liabilities
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]
Letter of credit
Letters of Credit Outstanding, Amount
Weighted Average Exercise Price per Share, Stock Options outstanding, Beginning Balance
Weighted Average Exercise Price per Share, Stock Options outstanding, Ending Balance
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]
Fair Value, Recurring and Nonrecurring [Table]
Additional Paid In Capital
Additional Paid-in Capital [Member]
Measurement Frequency
Measurement Frequency [Domain]
Statement of Income Location, Balance [Axis]
Income Statement Location
Trading Symbol
Trading Symbol
Risk-free interest rate, maximum
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Employee-related Liabilities, Current, Total
Accrued compensation and benefits
Employee-related Liabilities, Current
Financing activities
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]
Development Revenue
Development Revenue [Member]
Development revenue.
Expected term (in years)
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term
Recurring basis
Fair Value, Recurring [Member]
Lessee, Operating Lease, Liability, to be Paid
Total undiscounted lease payments
Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Less: Imputed interest
Selling and Marketing Expense, Total
Sales and marketing
Selling and Marketing Expense
Noncash lease expense
Noncash Lease Expense
Noncash lease expense.
Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments
Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]
Equity Components
Equity Components [Axis]
Equity Component
Equity Component [Domain]
Asset Class
Asset Class [Axis]
Weighted Average Exercise Price per Share, Stock Options vested and exercisable
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Exercisable Weighted Average Exercise Price
Share based compensation arrangement by share based payment award options vested and exercisable weighted average exercise price.
Customer
Customer [Axis]
Additional milestone payment.
Additional milestone payment receivable
Additional Milestone Payment
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period
Option expiration period
Depreciation, Depletion and Amortization, Nonproduction
Depreciation, Depletion and Amortization, Nonproduction, Total
Depreciation and amortization expense
US Treasury and Government [Member]
U.S. Government Treasury Securities
U.S. Government Treasury and Agency Securities
Common stock voting rights description
Common Stock, Voting Rights
Statement of Comprehensive Income [Abstract]
Maximum
Maximum [Member]
Adjustments to additional paid in capital capital contributions.
Adjustments To Additional Paid In Capital Capital Contributions
Capital contributions for Digital Biotechnologies, Inc.
Statistical Measurement
Statistical Measurement [Axis]
Weighted Average Exercise Price per Share, Stock Options exercised
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Non-current deferred revenue
Deferred revenue, less current portion
Contract with Customer, Liability, Noncurrent
One-time Termination Benefit
One-time Termination Benefits [Member]
Common Stock, Value, Issued
Common stock: $0.0001 par value, 340,000,000 shares authorized at March 31, 2026 and December 31, 2025; 159,697,221 and 153,779,418 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively
Additional transaction price of regulatory milestone.
Additional Transaction Price Of Regulatory Milestone
Additional transaction price of regulatory milestone payment
Immune medicine business member.
Immune Medicine Business [Member]
Immune Medicine
Ending Balance
Equity, Including Portion Attributable to Noncontrolling Interest
Total shareholders’ equity
Beginning Balance
Laboratory Equipment
Equipment [Member]
Medicare Reimbursements
Medicare Reimbursements [Member]
Medicare Reimbursements.
Preferred stock authorized
Preferred Stock, Shares Authorized
Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest, Total
Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest
Add: Comprehensive income attributable to noncontrolling interest
Operating expenses
Total operating expenses
Costs and Expenses
Debt Security Category
Debt Security Category [Axis]
Employee Stock Purchase Plan
Employee Stock [Member]
Revenue
Revenue from Contract with Customer [Text Block]
Entity Registrant Name
Entity Registrant Name
Unrealized Loss
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Customer Concentration Risk
Customer Concentration Risk [Member]
Lessee Disclosure [Abstract]
Additional Paid in Capital, Total
Additional paid-in capital
Additional Paid in Capital
MRD business segment member.
MRD Business Segment [Member]
MRD
Measurement Frequency
Measurement Frequency [Axis]
Contingent Consideration by Type
Business Combination, Contingent Consideration, Type [Axis]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Entity Common Stock, Shares Outstanding
Entity Common Stock, Shares Outstanding
Concentrations of Risk
Concentration Risk, Credit Risk, Policy [Policy Text Block]
Accumulated Other Comprehensive Income (Loss), Net of Tax, Total
Accumulated Other Comprehensive Income (Loss), Net of Tax
Accumulated other comprehensive (loss) gain
Consolidation Items [Axis]
Payments to Acquire Property, Plant, and Equipment, Total
Purchases of property and equipment
Payments to Acquire Property, Plant, and Equipment
Restricted Stock Units Outstanding, Granted
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period
Award granted
M R D Development Agreements [Member]
MRD development agreements.
MRD Development Agreements
Revenue recognition expected period
Revenue Recognition Expected Period
Revenue recognition expected period.
Total assets
Assets
Restructuring Cost [Table]
Restricted Stock Units Outstanding, Vested
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period
Earnings Per Share, Diluted, Total
Earnings Per Share, Diluted
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted
Schedule of Segment Reporting Information, by Segment [Table Text Block]
Schedule of Segment Information, Including Significant Segment Expenses
Operating Segments [Member]
Operating Segments
Long-Term Contract with Customer [Member]
Long-Term Contract with Customer
Title of Individual
Title and Position [Domain]
City Area Code
City Area Code
Additions to deferred revenue during the period
Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination
Purchase agreement, second payment date
Purchase Agreement Second Payment Date
Purchase agreement second payment date.
Basis of Presentation and Principles of Consolidation
Basis Of Presentation And Principles Of Consolidation Policy Policy [Text Block]
Basis of presentation and principles of consolidation policy.
Counterparty Name [Domain]
Segment Reporting Information [Line Items]
Property, Plant and Equipment, Net, Total
Property and equipment, net
Property, Plant and Equipment, Net
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]
Goodwill
Cash, cash equivalents and restricted cash at beginning of year
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation
Cash, cash equivalents and restricted cash at end of period
Total cash, cash equivalents and restricted cash at end of period
Corporate Bonds
Corporate Bond Securities [Member]
Non-refundable upfront payments received
Non Refundable Upfront Payments Received
Non-refundable upfront payments received.
Operating Income (Loss)
Loss from operations
Accumulated Deficit
Retained Earnings [Member]
Contingent Consideration Type
Business Combination, Contingent Consideration, Type [Domain]
Share-Based Payment Arrangement, Noncash Expense, Total
Share-based compensation expense
Share-Based Payment Arrangement, Noncash Expense
Share-based compensation expense
Genentech, Inc. and Roche Group
Genentech Inc And Roche Group [Member]
Genentech, Inc. and Roche Group.
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months
Less than 12 months, Fair Value
Operating lease liabilities, less current portion
Operating Lease, Liability, Noncurrent
Level 1
Fair Value, Inputs, Level 1 [Member]
Class Of Stock [Line Items]
Class of Stock [Line Items]
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Cash provided by financing activities
Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Corporate Debt Securities [Member]
Corporate Bonds
Debt Securities Available For Sale [Table]
Debt Securities, Available-for-Sale [Table]
Entity Interactive Data Current
Entity Interactive Data Current
Deferred revenue
Increase (Decrease) in Contract with Customer, Liability
Income Statement Location
Statement of Income Location, Balance [Domain]
Operating activities
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]
Proceeds from Contributed Capital
Proceeds from capital contributions for Digital Biotechnologies, Inc.
Investment amortization
Accretion (Amortization) of Discounts and Premiums, Investments
Schedule of Concentrations of Risk Percentage
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]
Entity Tax Identification Number
Entity Tax Identification Number
Revenues [Abstract]
Share Based Compensation Arrangement By Share Based Payment Award Vested And Exercisable Options Outstanding Weighted Average Remaining Contractual Term
Share based compensation arrangement by share based payment award vested and exercisable options outstanding weighted average remaining contractual term.
Weighted-average remaining contractual life for stock options vested and exercisable
Local Phone Number
Local Phone Number
Unrecognized Share-Based Compensation Expense
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
Restructuring costs
Restructuring Costs
Restructuring Costs, Total
Accounting Policies [Abstract]
Disaggregation Of Revenue [Line Items]
Disaggregation of Revenue [Line Items]
Revenue from collaboration agreement
Revenue
Revenue from Contract with Customer, Excluding Assessed Tax
Lessee, Operating Lease, Liability, to be Paid, Year Four
2030
Commercial Paper [Member]
Commercial Paper
Shares available for future issuance
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant
Shares available for grant at March 31, 2026
Shares available for grant at December 31, 2025
Remaining Weighted-Average Recognition Period (in years)
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition
Schedule Of Stock By Class [Table]
Stock, Class of Stock [Table]
Entity Emerging Growth Company
Entity Emerging Growth Company